Oncology & Cancer

Entrectinib gets edge over crizotinib against ROS1+ lung cancer

Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials are created equal, and ...

Other

The 'AI turn' for digital health: A futuristic view

The unprecedented implications of digital health innovations, being co-produced by the mainstreaming and integration of artificial intelligence (AI), the Internet of Things (IoT), and cyber-physical systems (CPS) in healthcare, ...